United Therapeutics (NASDAQ:UTHR) Releases Earnings Results

United Therapeutics (NASDAQ:UTHR) issued its earnings results on Wednesday. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54, Briefing.com reports. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The company had revenue of $677.70 million during the quarter, compared to analyst estimates of $620.31 million. During the same quarter last year, the business posted $4.86 EPS. The company’s revenue for the quarter was up 33.7% on a year-over-year basis.

United Therapeutics Trading Up 1.6 %

UTHR stock traded up $3.96 during midday trading on Thursday, reaching $259.10. The company’s stock had a trading volume of 427,483 shares, compared to its average volume of 452,315. United Therapeutics has a 52 week low of $204.44 and a 52 week high of $261.54. The stock has a market cap of $11.50 billion, a PE ratio of 13.06 and a beta of 0.54. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05. The business’s 50-day simple moving average is $235.34 and its 200-day simple moving average is $229.00.

Analyst Upgrades and Downgrades

UTHR has been the subject of several analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $308.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. SVB Leerink assumed coverage on shares of United Therapeutics in a research report on Monday, February 5th. They set an “outperform” rating and a $330.00 target price for the company. Oppenheimer upped their price objective on shares of United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday. The Goldman Sachs Group raised shares of United Therapeutics from a “sell” rating to a “neutral” rating and increased their price target for the stock from $213.00 to $215.00 in a research report on Monday, February 12th. Finally, StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 11th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $306.00.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 15,000 shares of the stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $236.59, for a total value of $3,548,850.00. Following the sale, the chief executive officer now directly owns 130 shares in the company, valued at $30,756.70. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CEO Martine A. Rothblatt sold 15,000 shares of the firm’s stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $236.59, for a total transaction of $3,548,850.00. Following the sale, the chief executive officer now directly owns 130 shares in the company, valued at $30,756.70. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $235.35, for a total transaction of $847,260.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at $30,595.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 138,190 shares of company stock valued at $32,643,561. 12.50% of the stock is currently owned by insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.